Mar 3, 2026 | 340B, Litigation, News and Updates
On March 3, 2026, the U.S. District Court for the District of Columbia struck down the Health Resources & Services Administration’s (HRSA’s) requirement that for new offsite outpatient facilities to be eligible to use 340B discounted drugs they must...
Sep 24, 2025 | Litigation, Medicaid
A Texas District Court judge granted Texas’ motion for summary judgment in the state’s lawsuit challenging two CMS Informational Bulletins and provisions in CMS’ 2024 Medicaid managed care rule that prohibit certain voluntary redistribution agreements among private...
Sep 22, 2021 | 340B, Litigation, News and Updates
The Health Resources and Services Administration (HRSA) has taken additional steps to require 340B drug discounts when drugs are dispensed through contract pharmacies. On September 22, HRSA followed up on earlier letters to six manufacturers refusing contract pharmacy...
Jun 18, 2021 | 340B, Litigation
The Health and Resource Service Administration (HRSA) announced June 18, in connection with the ongoing AstraZeneca case, that is withdrawing its December 2020 contract pharmacy Advisory Opinion “to avoid confusion and unnecessary litigation.” Despite withdrawal of...
Jun 16, 2021 | 340B, Litigation, News and Updates
A district court judge in Delaware issued an opinion denying the government’s motion to dismiss a lawsuit regarding a December 2020 Advisory Opinion issued by the Health and Resource Service Administration (HRSA). The judge concluded that the 340B statute is silent as...
Jun 10, 2021 | 340B, Litigation, News and Updates
On June 10, 2021, Eli Lilly became the third manufacturer to response to HRSA’s May 17th Cease and Desist letter on 340B drug pricing. The response details Eli Lilly’s rejection of HRSA’s reasoning in its Cease and Desist letter, arguing that the agency’s reasoning is...
